- Home
- CERT
CERT
Certara Inc.
as 12-17-2024 4:00pm EST
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | RADNOR |
| Market Cap: | 1.9B | IPO Year: | 2020 |
| Target Price: | $15.92 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.20 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.41 - $19.87 | Next Earning Date: | 11-06-2024 |
| Revenue: | $372,797,000 | Revenue Growth: | 5.62% |
| Revenue Growth (this year): | 10.2% | Revenue Growth (next year): | 10.43% |
Stock Insider Trading Activity of Certara Inc. (CERT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| SMITH PATRICK F | CERT | PRESIDENT, DRUG DEV SOLUTIONS | Oct 7 '24 | Sell | $11.03 | 5,409 | $59,661.27 | 50,091 |
Latest Certara Inc. News
CERT Breaking Stock News: Dive into CERT Ticker-Specific Updates for Smart Investing
Argus Research
8 days ago
CERT: Raising target price to $10.00
Insider Monkey
12 days ago
Cautious Spending By Large Biopharma Client Dragged Certara (CERT) in Q3
Argus Research
15 days ago
CERT: What does Argus have to say about CERT?
GlobeNewswire
16 days ago
Certara Showcases 2024 Research Wins With Over 100 Papers Published
Simply Wall St.
20 days ago
Exploring Three High Growth Tech Stocks In The United States
Argus Research
22 days ago
CERT: What does Argus have to say about CERT?
Insider Monkey
a month ago
Soft Biotech Funding and Cost-Cutting Dragged Certara (CERT) in Q3
Argus Research
a month ago
CERT: Raising target price to $10.00
Compare CERT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CERT Certara Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.